文献速递母胎医学

无创产前筛查结果正常时胎儿染色体异常的残留风险:一项回顾性研究

Residual Risks of Fetal Chromosome Aberrations When Cell-Free DNA Prenatal Screening Is Normal: A Retrospective Study.
PubMed 文献 · Prenat Diagn · 2025-09-24

该回顾性单中心研究纳入2017年4月至2021年3月间46,007例无创产前筛查(cfDNA)结果正常的孕妇,分为仅覆盖13/18/21染色体的靶向cfDNA组和覆盖全部常染色体的全基因组cfDNA组,随访细胞基因组学数据。结果发现总体致病性染色体异常残留风险低,但超声异常时风险显著升高,支持即使cfDNA正常也应进行侵入性检测。

要点

  • cfDNA结果正常者总体致病性染色体异常残留风险低,靶向组为1:641,全基因组组为1:699。
  • 超声异常胎儿中残留风险显著升高,靶向组为1:8,全基因组组为1:12。
  • 超声异常时即使cfDNA正常,也支持进行侵入性检测。

核心结论

  • cfDNA结果正常者选择筛查时致病性拷贝数变异(CNV)的残留风险低。
  • 当检出超声异常时,该风险严重增加,支持即使cfDNA结果正常也进行侵入性检测。
  • 这些数据可用于检测前和检测后咨询。

研究设计与样本

  • 回顾性单中心研究,于2017年4月至2021年3月期间开展。
  • 共46,007例孕妇获得cfDNA筛查正常结果。
  • 队列分为仅13/18/21染色体正常的靶向cfDNA组和全部常染色体正常的全基因组cfDNA组(检测分辨率约10-20 Mb)。
  • 细胞基因组学随访包括产前或产后染色体微阵列(CMA)数据。

主要发现

  • 46,007例cfDNA结果正常者中,806例(1.8%)转诊进行CMA检测;其中多数(511/806)因超声异常转诊。
  • 整个靶向cfDNA队列中致病性染色体异常的残留风险为1:641(0.15%)。
  • 全基因组cfDNA组中致病性染色体异常的残留风险为1:699(0.14%)。
  • 超声异常胎儿中,靶向cfDNA组致病性染色体异常的残留风险为1:8(13.3%),全基因组cfDNA组为1:12(8.1%)。

临床怎么用

  • cfDNA结果正常者总体致病性CNV残留风险低,可用于检测前和检测后咨询。
  • 当检出超声异常时,即使cfDNA结果正常,也支持进行侵入性检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To estimate the residual risk of fetal chromosomal aberrations in pregnant women with normal cell-free DNA (cfDNA) screening results to refine prenatal counseling. METHODS: A retrospective single-center study was conducted between April-2017 and March-2021. In total, 46,007 women received a normal cfDNA screening result. The cohort was subdivided into women receiving normal results for only chromosomes 13/18/21 (targeted cfDNA) and all autosomes (genome-wide cfDNA with a test resolution ∼10-20 Mb). Cytogenomic follow-up included prenatal or postnatal chromosomal microarray (CMA) data. RESULTS: Out of 46,007 women with normal cfDNA results, 806 (1.8%) were referred for CMA testing; the majority (511/806) were referred due to ultrasound anomalies. The residual risk for a pathogenic chromosomal aberration in the entire targeted cfDNA cohort was 1:641 (0.15%); in the genome-wide cfDNA group, it was 1:699 (0.14%). For fetuses with ultrasound anomalies, the residual risk for a pathogenic chromosomal aberration in the targeted-cfDNA group was 1:8 (13.3%), and 1:12 (8.1%) in the genome-wide cfDNA group. CONCLUSIONS: The residual risk of a pathogenic CNV after a normal cfDNA result is low in women who opt for screening. However, when ultrasound anomalies are detected, this risk is severely increased, justifying the use of invasive testing even with normal cfDNA results. These figures can be used for pre-and-post-test counseling.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Iglesias AI, Van Opstal D, Thurik FF, et al. Residual Risks of Fetal Chromosome Aberrations When Cell-Free DNA Prenatal Screening Is Normal: A Retrospective Study. Prenat Diagn. 2025. PMID: 40992929. doi:10.1002/pd.6888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。